Ethyl 2-(difluoromethyl)-2,5-bis(methoxycarbonylamino)pentanoate | 1242270-40-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ethyl 2-(difluoromethyl)-2,5-bis(methoxycarbonylamino)pentanoate
• CAS: 1242270-40-1
• 化学式: C₁₂H₂₀F₂N₂O₆
• 分子量: 326.297
• InChiKey: HYNYMGJCWDCKHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  氯甲酸甲酯 、 ethyl 2,5-diamino-2-(difluoromethyl)pentanoate 生成 Ethyl 2-(difluoromethyl)-2,5-bis(methoxycarbonylamino)pentanoate
  参考文献：
  名称：

  [EN] POLYAMINE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE
  [FR] INHIBITEUR DE POLYAMINE POUR LE TRAITEMENT ET LA PRÉVENTION DE LA MALADIE DE PARKINSON

  摘要：

  本文揭示了治疗涉及α-突触核聚集的疾病的方法，使用以下物质之一：（1）减少多胺量的化合物，以有效减少α-突触核聚集；（2）抑制多胺合成的化合物，以有效减少α-突触核聚集；或（3）抑制α-突触核聚集的化合物，以有效减少α-突触核聚集。还揭示了一种在脑细胞中减少α-突触核聚集量的方法，使用以下物质之一：（1）减少多胺量的化合物，以有效减少α-突触核聚集；（2）抑制多胺合成的化合物，以有效减少α-突触核聚集；或（3）抑制α-突触核聚集的化合物，以有效减少α-突触核聚集。本文还揭示了可用于上述方法的化合物。

  公开号：

  WO2010098886A1

文献信息

• POLYAMINE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE
  申请人：Small Scott A.

  公开号：US20120129939A1

  公开（公告）日：2012-05-24

  Disclosed herein are methods for treating a disease involving α-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α-synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Also disclosed are methods for reducing the amount of α-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α-synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods.
• [EN] POLYAMINE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE<br/>[FR] INHIBITEURS DE POLYAMINES DESTINÉS À TRAITER ET À PRÉVENIR LA MALADIE DE PARKINSON
  申请人：UNIV COLUMBIA

  公开号：WO2012115608A2

  公开（公告）日：2012-08-30

  Disclosed herein are methods for treating a disease involving α-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits a- synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Also disclosed are methods for reducing the amount of α-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce a-synucleic aggregation; or (3) a compound which inhibits a- synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods.
• [EN] POLYAMINE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE<br/>[FR] INHIBITEUR DE POLYAMINE POUR LE TRAITEMENT ET LA PRÉVENTION DE LA MALADIE DE PARKINSON
  申请人：UNIV COLUMBIA

  公开号：WO2010098886A1

  公开（公告）日：2010-09-02

  Disclosed herein are methods for treating a disease involving α-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α- synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Also disclosed are methods for reducing the amount of α-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α-synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods.

  本文揭示了治疗涉及α-突触核聚集的疾病的方法，使用以下物质之一：（1）减少多胺量的化合物，以有效减少α-突触核聚集；（2）抑制多胺合成的化合物，以有效减少α-突触核聚集；或（3）抑制α-突触核聚集的化合物，以有效减少α-突触核聚集。还揭示了一种在脑细胞中减少α-突触核聚集量的方法，使用以下物质之一：（1）减少多胺量的化合物，以有效减少α-突触核聚集；（2）抑制多胺合成的化合物，以有效减少α-突触核聚集；或（3）抑制α-突触核聚集的化合物，以有效减少α-突触核聚集。本文还揭示了可用于上述方法的化合物。